Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
AMRN | US
0.06
0.41%
Healthcare
Biotechnology
30/06/2024
03/06/2026
14.53
14.47
14.78
14.20
Amarin Corporation plc a pharmaceutical company engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States European countries Canada Lebanon and the United Arab Emirates. It offers VASCEPA a prescription-only omega-3 fatty acid product used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co. Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin Ireland.
View LessStrength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
17.9%1 month
22.9%3 months
36.3%6 months
49.2%-
500.00
0.42
0.01
0.01
-5.80
0.08
-1.74
-23.79M
5.97B
5.97B
-
-0.78
-94.20
-15.80
-5.98
26.50
4.40
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.77
Range1M
1.78
Range3M
4.04
Rel. volume
1.10
Price X volume
737.09K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Nuvalent Inc. Class A Common Stock | NUVL | Biotechnology | 90.18 | 6.36B | -1.28% | n/a | 0.00% |
| TG Therapeutics Inc | TGTX | Biotechnology | 40.11 | 6.21B | 9.47% | 34.28 | 63.38% |
| Grifols S.A | GRFS | Biotechnology | 7.47 | 5.83B | -2.10% | 33.27 | 190.24% |
| Vaxcyte Inc. | PCVX | Biotechnology | 46.93 | 5.81B | -1.01% | n/a | 1.29% |
| Protagonist Therapeutics Inc | PTGX | Biotechnology | 95.41 | 5.62B | 2.34% | 17.27 | 2.03% |
| PTC Therapeutics Inc | PTCT | Biotechnology | 68.68 | 5.28B | 0.66% | n/a | -40.35% |
| Rhythm Pharmaceuticals Inc | RYTM | Biotechnology | 84.71 | 5.18B | 0.43% | n/a | 642.15% |
| Centessa Pharmaceuticals plc American Depositary Shares | CNTA | Biotechnology | 39.85 | 5.12B | -0.13% | n/a | 29.85% |
| IBRX | IBRX | Biotechnology | 7.18 | 5.00B | -0.69% | n/a | -143.04% |
| Praxis Precision Medicines Inc | PRAX | Biotechnology | 278.93 | 4.95B | 8.08% | n/a | 0.46% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| FBIN | FBIN | Building Products & Equipment | 38.85 | 4.82B | -0.92% | 25.57 | 130.24% |
| Thor Industries Inc | THO | Recreational Vehicles | 79.76 | 4.22B | 2.86% | 23.44 | 27.88% |
| Polaris Industries Inc | PII | Recreational Vehicles | 68.32 | 3.81B | 0.10% | 14.48 | 170.51% |
| Harley-Davidson Inc | HOG | Recreational Vehicles | 24.25 | 3.19B | -1.54% | 7.33 | 218.58% |
| Pitney Bowes Inc | PBI | Building Products & Equipment | 16.5 | 2.96B | -1.32% | n/a | -571.93% |
| LCI Industries | LCII | Recreational Vehicles | 106.78 | 2.72B | -0.04% | 25.82 | 77.66% |
| VeriFone Systems Inc | PAY | Building Products & Equipment | 21.11 | 2.63B | -5.55% | 102.46 | 2.10% |
| Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 50.07 | 1.58B | 2.06% | 51.60 | 88.92% |
| HNI Corporation | HNI | Building Products & Equipment | 30.17 | 1.42B | -1.89% | 22.12 | 76.47% |
| ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 12.9 | 1.29B | -3.52% | n/a | 19.46% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -5.80 | - | Cheaper |
| Ent. to Revenue | 0.08 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.42 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 36.29 | - | Lower Risk |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 5.97B | - | Market Leader |